Sunday 18 October 2026
Export GNLX’s income statement to Excel — free account
Genelux Corporation
GNLX Healthcare Biotechnology
Genelux Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8,000.00, roughly unchanged from fiscal 2024. In the quarter to June 2026, EPS fell 5.00% and free cash flow fell 11.2%, each against the same quarter a year earlier.
2.42
0.06
−2.42%
Follow GNLX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Altman Z-Score |
(13.06) | (7.02) | 11.18 | — | — | — | — |
P/S ratio |
14.41 | 6.60 | 0.00 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(55.62) | (21.82) | (25.13) | (151.70) | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
P/Operating CF |
(26.15) | (17.25) | (52.50) | (36.93) | — | — | — |
P/B ratio |
14.04 | 2.83 | 18.63 | 0.00 | — | — | — |
Price to Tangible BV |
14.04 | 2.83 | 18.63 | 0.00 | — | — | — |
EV/Sales |
13.87 | 4.61 | 0.00 | 0.00 | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
(6.17) | (2.44) | (17.17) | (17.98) | — | — | — |
EV/FCF |
(5.92) | (2.40) | (16.34) | (17.73) | — | — | — |
Quick Ratio |
2.34 | 4.48 | 3.54 | 0.01 | 0.20 | 0.78 | 0.03 |
Current Ratio |
2.43 | 4.57 | 3.69 | 0.06 | 0.26 | 0.79 | 0.04 |
Net Debt/EBITDA |
0.44 | 0.96 | 1.00 | (3.69) | (0.95) | (1.25) | (1.69) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 154.11% | 217.93% | 186.04% | 547.82% |
Debt/Equity |
0.00 | 0.00 | 0.00 | (0.24) | (0.53) | (1.15) | (0.72) |
Asset Turnover |
0.00 | 0.00 | 0.01 | 1.62 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.79 | 0.71 | 0.72 | 0.69 | 0.40 | 0.53 | 0.62 |
Capex/Depreciation |
(61.00) | 0.73 | (0.94) | (0.06) | 0.00 | 0.00 | 0.00 |
Interest Coverage |
— | — | (139.68) | (2.62) | (11.97) | (20.35) | (28.57) |
| (170.00%) | (130.58%) | 346.52% | 15.11% | 58.69% | 57.43% | 0.00% | |
| (119.62%) | (95.41%) | (169.32%) | (76.25%) | (147.99%) | (157.82%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(290.25%) | (115.05%) | (150.36%) | 17.90% | 105.58% | 2,414.69% | 100.92% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
248,137.50% | 237,475.00% | 7,510.00% | 82.02% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
167,137.50% | 158,825.00% | 6,804.71% | 45.20% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
73,387.50% | 71,725.00% | 1,479.41% | 21.82% | 0.00% | — | — |
Graham Net Nets |
0.05 | 0.31 | 0.04 | (0.70) | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 7.10 | — | — | — |
Earnings Yield |
(19.72%) | (40.68%) | (8.14%) | (9.29%) | — | — | — |
Free Cash Flow Yield |
(16.27%) | (29.11%) | (5.87%) | (6.46%) | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.01 | 1.21 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.68) | (0.67) | (0.83) | (0.39) | (0.73) | (0.31) | (0.31) |
Capex per Share |
(0.03) | (0.01) | (0.04) | (0.01) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.71) | (0.69) | (0.87) | (0.40) | (0.73) | (0.31) | (0.31) |
Cash per Share |
0.39 | 0.98 | 0.95 | 0.04 | 0.50 | 0.48 | 0.02 |
Shareholders Equity per Share |
0.31 | 0.84 | 0.80 | (3.93) | (3.67) | (0.96) | (1.05) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.31 | 0.84 | 0.80 | (3.93) | (3.67) | (0.96) | (1.05) |
Free Cash Flow |
(26.37) | (21.61) | (21.30) | (3.62) | (6.58) | (7.20) | (7.22) |
Working Capital |
8.91 | 24.65 | 17.65 | (29.73) | (16.66) | (3.02) | (14.17) |
Capital Expenditures |
(1.10) | (0.38) | (1.02) | (0.05) | — | (0.02) | (1.77) |
Net Current Asset Value |
7.65 | 23.11 | 15.78 | (39.42) | (35.41) | (25.19) | (27.54) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
137.25 | 47.63 | 6.03 | 0.00 | — | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | |||||||
Depreciation/Fixed assets |
0.01 | (0.40) | 0.93 | 1.26 | 0.65 | 0.27 | 0.18 |
Cash ROIC |
(100.87%) | (37.80%) | (49.92%) | 13.48% | 60.37% | (48.83%) | 112.65% |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
4.96 | 4.68 | 5.28 | 5.62 | — | — | — |
Average Assets |
26.87 | 31.30 | 16.71 | 6.83 | 11.07 | 8.64 | — |
Average Common Equity |
18.91 | 22.87 | (8.17) | (34.47) | (27.90) | (23.75) | — |
Columns are period end dates